Jan 29, 2021 08:30 JST
Source: Olympus
|
|
Olympus to Acquire Quest Photonic Devices B.V. to Bolster Surgical Endoscopy Capabilities
Strategic acquisition of Dutch multispectral imaging leader drives growth of Olympus' Surgical Endoscopy business
Tokyo / Hamburg, Jan 29, 2021 - (JCN Newswire) - Olympus Corporation (TSE: 7733) today announced that it has entered into an agreement to acquire Quest Photonic Devices B.V. (Quest; CEO: Richard Meester) for up to EUR50 million including milestone payments to strengthen its surgical endoscopy capabilities.
Headquartered in the Netherlands, Quest offers advanced fluorescence imaging systems (FIS) for the medical field, enabling more surgical endoscopy capabilities, compared to conventional imaging technologies.
Fluorescence imaging refers to special light imaging technologies that utilize the properties of fluorescent dyes directed to specific anatomical structures. By using targeted dyes, in combination with specific light wavelengths, tissues or lesions that are nearly invisible under normal white light become visible. Olympus' existing laparoscopic imaging system, VISERA ELITE II, is already equipped with fluorescence imaging technology. VISERA ELITE II uses near-infrared light to identify blood vessels or lymph nodes under the surface tissues, aiming to assist surgeons in performing safer procedures with lower complication risks. The Quest technology acquired is intended to expand opportunities for Olympus in this field.
Making the Invisible Visible
Quest offers innovative technologies for multi-spectral imaging and imaging systems for medical applications, ranging from fluorescence imaging to photodynamic therapy. The acquisition strengthens Olympus' position as a world leader in medical imaging solutions, and delivers innovative capabilities (including 3D and 4K imaging) to surgeons, to "make the invisible visible."
Quest's lead product line is the Quest Spectrum Fluorescence Imaging System, which enables fluorescence-guided surgery for open and minimally invasive procedures. Kanichi Matsumoto, global head of Surgical Endoscopy at Olympus, said: "We are delighted to incorporate Quest's advanced FIS capabilities into our comprehensive medical imaging portfolio. The combination of the Quest Spectrum product line's leading FIS technologies with Olympus' existing laparoscopic imaging system VISERA ELITE II will enable Olympus to offer surgeons a wide range of high-quality fluorescence imaging solutions."
New Applications and Market Growth
The global market for FIS devices is expected to grow at a compounding annual rate of more than 12%, from around US$310 million in 2018 to over US$827 million in 2027*. Increasing demand for minimally invasive procedures and reconstructive surgery is helping to drive FIS growth worldwide. Furthermore, application of the FIS technology is expected to expand over the coming years, as additional fluorescent dyes are paired with targeted antibodies. Among other applications, molecular imaging will allow healthcare professionals to visualize cancerous lesions in vivo and perform cancer surgery in unprecedented ways, potentially lowering recurrence rates.
Quest also works with biotechnology companies that are developing next-generation molecular imaging dyes. These innovative dyes may enable Quest's technology to advance diagnostic opportunities in fluorescence-guided cancer surgery.
*Source: Transparency Market Research; Near-Infrared Fluorescence Imaging System Market Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2019-2027.
About Quest
Quest Photonic Devices B.V. is a multispectral imaging leader and focuses on the medical markets of fluorescence image-guided surgery and cancer-targeted probes. Quest's next-generation Spectrum Florescence Imaging System has the ability to "see through tissue" with enhanced sensitivity, capable of accessing otherwise inaccessible information to aid the surgeon in improving clinical outcomes.
About Olympus' Medical business
As a leading medical technology company, Olympus' Medical business uses innovative capabilities in medical technology, therapeutic intervention, and precision manufacturing to help healthcare professionals deliver diagnostic, therapeutic, and minimally invasive procedures to improve clinical outcomes, reduce overall costs, and enhance the quality of life for patients and their safety. Olympus' Medical portfolio includes endoscopes, laparoscopes, and video imaging systems, as well as surgical energy devices, system integration solutions, medical services, and a wide range of endotherapy instruments for endoscopic and therapeutic applications. For more information, visit www.olympus-global.com.
For questions or additional information, please contact:
Europe, Middle East and Africa Matthias Gengenbach +49 15142369420 matthias.gengenbach@olympus-europa.com
Japan and Asia Pacific Yuka Horimoto +81-90-2490-1071 yuka_horimoto@ot.olympus.co.jp
Source: Olympus Sectors: Healthcare & Pharm, MedTech
Copyright ©2024 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
|
Latest Press Release
myBillBook Leverages CleverTap to Elevate Customer Engagement and Drive Revenue Growth Nov 14, 2024 20:00 JST
| ULVAC Launches Oil Rotary Vacuum Pump Gv135 Nov 14, 2024 10:00 JST
| MHI Publishes MHI REPORT 2024 Nov 13, 2024 16:52 JST
| SoftBank Corp. and Fujitsu Strengthen Partnership for Realization of AI-RAN Commercialization Nov 13, 2024 12:38 JST
| Predictive Heart Monitoring Startup, GPx, Secures New Investment From NEC X; Joins Elev X! Boost Venture Studio Program Nov 13, 2024 12:05 JST
| NEC receives order for next-generation supercomputer system from Japan's National Institutes for Quantum Science and Technology and National Institute for Fusion Science Nov 13, 2024 11:16 JST
| All-New Triton Wins Special Award at the RJC Car of the Year for 2025 Nov 12, 2024 22:09 JST
| Toyota: HySE to participate in the Dakar 2025 "Mission 1000 ACT2" with the HySE-X2, to tackle further technical challenges Nov 12, 2024 20:04 JST
| NEC participates in COP29 climate change conference Nov 12, 2024 19:25 JST
| JA Mitsui Leasing and Fujitsu collaborate on simulation-driven field trials to optimize commercial EV adoption and drive decarbonization Nov 12, 2024 13:57 JST
| Macnica publishes Integrated Report on the theme of 'An Introductory Guide to Macnica's Mechanism' Nov 12, 2024 13:00 JST
| Hitachi: Established the Open Source Program Office (OSPO) to Globally Lead the Strategic Utilization of OSS Nov 11, 2024 10:31 JST
| Transgene and NEC Present New Data Confirming Clinical Proof of Principle for Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at SITC 2024 Nov 08, 2024 10:31 JST
| Hitachi High-Tech and University of Tokyo Promote Joint Research for the Practical Application of High-resolution Laser-PEEM in the Semiconductor Field Nov 07, 2024 18:19 JST
| Mitsubishi Motors Acquires Its Own Shares from Nissan Nov 07, 2024 17:20 JST
| Honda Signs Sponsorship Agreement to Provide Electrified Vehicles at World Athletics Championships Tokyo 25 Nov 07, 2024 17:10 JST
| Home of Fujitsu joint conservation project designated as first Nationally Certified Sustainably Managed Natural Site in Okinawa Nov 07, 2024 14:51 JST
| NEC and NEC Bio publish foundational work on T Cell Receptor engineering using proprietary generative AI at the Society for Immunotherapy of Cancer annual meeting Nov 07, 2024 11:40 JST
| Anime Tokyo Station 1st Anniversary Event: Celebrating one year since the opening of the new hub for sharing Japanese anime Nov 07, 2024 11:00 JST
| 57% of Banking Executives Struggle with Data Silos, Blocking AI-Driven Personalization, CleverTap's New Report Highlights Nov 06, 2024 15:30 JST
|
More Latest Release >>
|